Akonni Biosystems

Akonni Biosystems awarded NIH contract to develop a simple, cost-effective device to purify DNA from sputum for TB testing

FREDERICK, Md., March 10, 2017 -- Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $300K contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will enable Akonni to accelerate development of a low-cost, simple, field-based nucleic acid extraction device – a highly sought-after solution for a widely unmet need in the field of global health.

Read More →

Page 1 of 1 · Total posts: 1